Literature DB >> 11327584

The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus.

A A Nikitenko1, Y E Raifeld, T Z Wang.   

Abstract

The design and synthesis of a new potent and selective inhibitor of the respiratory syncytial virus are described. This compound, RFI-641, emerged from analysis of the structure-activity relationship in a series of biphenyl triazine anionic compounds possessing specific anti-RSV activity. The key synthetic step involves coupling of diaminobiphenyl 11 with two equivalents of chlorotriazine 10 under microwave conditions. RFI-641 inhibited RSV in vitro and in vivo models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11327584     DOI: 10.1016/s0960-894x(01)00150-0

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

Review 1.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

2.  RFI-641, a potent respiratory syncytial virus inhibitor.

Authors:  Clayton C Huntley; William J Weiss; Anna Gazumyan; Aron Buklan; Boris Feld; William Hu; Thomas R Jones; Timothy Murphy; Antonia A Nikitenko; Bryan O'Hara; Gregory Prince; Susan Quartuccio; Yuri E Raifeld; Philip Wyde; John F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 3.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells.

Authors:  Ling Yi; Zhengquan Li; Kehu Yuan; Xiuxia Qu; Jian Chen; Guangwen Wang; Hong Zhang; Hongpeng Luo; Lili Zhu; Pengfei Jiang; Lirong Chen; Yan Shen; Min Luo; Guoying Zuo; Jianhe Hu; Deliang Duan; Yuchun Nie; Xuanling Shi; Wei Wang; Yang Han; Taisheng Li; Yuqing Liu; Mingxiao Ding; Hongkui Deng; Xiaojie Xu
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

6.  A classification study of respiratory Syncytial Virus (RSV) inhibitors by variable selection with random forest.

Authors:  Ming Hao; Yan Li; Yonghua Wang; Shuwei Zhang
Journal:  Int J Mol Sci       Date:  2011-02-21       Impact factor: 5.923

Review 7.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 8.  Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Authors:  Swapnil Subhash Bawage; Pooja Munnilal Tiwari; Shreekumar Pillai; Vida Dennis; Shree Ram Singh
Journal:  Adv Virol       Date:  2013-12-09

9.  Bioengineered in Vitro Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation.

Authors:  Juhi Chakraborty; Indranil Banerjee; Raju Vaishya; Sourabh Ghosh
Journal:  ACS Biomater Sci Eng       Date:  2020-11-16

Review 10.  Respiratory syncytial virus entry inhibitors targeting the F protein.

Authors:  Zhiwu Sun; Yanbin Pan; Shibo Jiang; Lu Lu
Journal:  Viruses       Date:  2013-01-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.